Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 7:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 11,343 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer, Malignant Tumors Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Robotic Surgery in the Seated Position for Benign and Malignant Lesions of the Head and Neck

NCT02792322
View directory record Official record
Conditions
Oropharyngeal Neoplasms, Head and Neck Cancer
Interventions
Transoral Robotic Surgery (TORS) with the daVinci Robotic Surgical System device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 4, 2026, 7:51 PM EDT
Terminated Phase 1 Interventional

To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.

NCT02679131
View directory record Official record
Conditions
Relapsed/Refractory Solid Tumors/Hematological Malignancies
Interventions
Belinostat
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Whittier, California • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 4, 2026, 7:51 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

NCT00032045
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
gp100 antigen, incomplete Freund's adjuvant, ipilimumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 4, 2026, 7:51 PM EDT
Terminated Phase 1Phase 2 Interventional

Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma

NCT00358319
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Karenitecin, Valproic Acid
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 4, 2026, 7:51 PM EDT
Recruiting Phase 1Phase 2 Interventional

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

NCT06161519
View directory record Official record
Conditions
Glioma, Medulloblastoma, Ependymoma, Glioblastoma
Interventions
PLX038
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 4, 2026, 7:51 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function

NCT01443481
View directory record Official record
Conditions
Solid Tumors, Hepatic Impairment
Interventions
Dovitinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Los Angeles, California • Durham, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 4, 2026, 7:51 PM EDT
Terminated Phase 3 Interventional

Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors

NCT00031798
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Depression, Fatigue, Quality of Life
Interventions
methylphenidate hydrochloride, quality-of-life assessment, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
7
States / cities
Phoenix, Arizona • Decatur, Illinois • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Oct 4, 2026, 7:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Development of MR Spectroscopy and Imaging in Brain Cancers

NCT02731521
View directory record Official record
Conditions
Malignant Gliomas, Astrocytomas, Oligodendrogliomas
Interventions
3 Tesla Scanning, 7 Tesla Scanning
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Oct 4, 2026, 7:51 PM EDT
Enrolling by invitation Early Phase 1 Interventional Accepts healthy volunteers

Drug Screening Using IMD in Bladder Cancer

NCT06204614
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma
Interventions
Implantable Micro-Device, Methotrexate, Carboplatin, Avelumab, Paclitaxel, Vinblastine, Gemcitabine/Cisplatin I, Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab, Gemcitabine/Cisplatin II, Cisplatin, Nivolumab, Pembrolizumab, Gemcitabine/Carboplatin, Methotrexate/Vinblastine/Doxorubicin/Cisplatin, Gemcitabine/Cisplatin/Nivolumab, Erdafitinib, Paclitaxel/Docetaxel/Ifosfamide, Gemcitabine, Gemcitabine/Carboplatin/Nivolumab, Enfortumab, Sacituzumab
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 4, 2026, 7:51 PM EDT
Active, not recruiting No phase listed Observational

Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma

NCT06108206
View directory record Official record
Conditions
Glioblastoma, Anaplastic Astrocytoma, Astrocytoma, Anaplastic Oligodendroglioma
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 4, 2026, 7:51 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer

NCT00005049
View directory record Official record
Conditions
Colorectal Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Ovarian Cancer, Peritoneal Cavity Cancer, Small Intestine Cancer
Interventions
carboplatin, cisplatin, floxuridine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2011 · Synced Oct 4, 2026, 7:51 PM EDT
Completed No phase listed Observational

Psychological, Psychophysical and Epigenetic Determinants of Chronic Pain After Cytoreductive - Hyperthermic Intraoperative Chemotherapy

NCT05083338
View directory record Official record
Conditions
Appendix Carcinoma, Carcinomatosis, Colorectal Carcinoma, Gastric Carcinoma, Malignant Peritoneal Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Pain Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 4, 2026, 7:51 PM EDT
Active, not recruiting Phase 1 Interventional

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

NCT06325748
View directory record Official record
Conditions
AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
Interventions
SENTI-202
Biological
Lead sponsor
Senti Biosciences
Industry
Eligibility
18 Years to 74 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2040
U.S. locations
6
States / cities
Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 4, 2026, 7:51 PM EDT
Completed Phase 2 Interventional Results available

Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors

NCT00024258
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma
Interventions
arsenic trioxide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 4, 2026, 7:51 PM EDT
Completed Phase 1 Interventional

A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer

NCT01050985
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Temsirolimus and capecitabine
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 4, 2026, 7:51 PM EDT
Completed Phase 2 Interventional

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

NCT03113825
View directory record Official record
Conditions
Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast, Breast Cancer Female, Carcinoma, Ductal, Breast, Stage II Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer
Interventions
Investigational Imaging device, AVB-620
Device · Drug
Lead sponsor
Avelas Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
San Diego, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 4, 2026, 7:51 PM EDT
Completed Phase 4 Interventional

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

NCT00230217
View directory record Official record
Conditions
Tumors, Hyperuricemia, Tumor Lysis Syndrome
Interventions
Rasburicase (SR29142)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Not listed
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
Berkley, California • Denver, Colorado • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2009 · Synced Oct 4, 2026, 7:51 PM EDT
Completed Not applicable Interventional

Feasibility of a Creative Writing Intervention in an Advanced Cancer Population: A Single Arm, Consecutive Cohort Study

NCT02575898
View directory record Official record
Conditions
Primary Malignant Neoplasm of Lung, Primary Malignant Neoplasm of Gastrointestinal Tract
Interventions
First Session, Second Session, Third through Sixth Sessions
Other · Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 4, 2026, 7:51 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers

NCT00952185
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm, Viral Infection
Interventions
cytology specimen collection procedure, fluorescent antibody technique, assessment of therapy complications
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 4, 2026, 7:51 PM EDT
Not listed No phase listed Observational

A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders

NCT00596999
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
UCB and HPDSC
Procedure
Lead sponsor
Celgene Corporation
Industry
Eligibility
Up to 55 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Oct 4, 2026, 7:51 PM EDT
Recruiting Early Phase 1 Interventional

A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

NCT07017816
View directory record Official record
Conditions
CNS Malignancies, Medulloblastoma Recurrent, ATRT Recurrent, Pineoblastoma, Embryonal Neoplasm, Ependymoma Recurrent, High Grade Gliomas
Interventions
SGT-53, hypofractionated radiotherapy with immunotherapy, Nivolumab
Drug · Radiation
Lead sponsor
Children's National Research Institute
Other
Eligibility
3 Years to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 4, 2026, 7:51 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

NCT02817633
View directory record Official record
Conditions
Neoplasms
Interventions
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
64
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 4, 2026, 7:51 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Selinexor Combination Ph 1 Study

NCT05177276
View directory record Official record
Conditions
Solid Tumor Malignancy
Interventions
Selinexor, Irinotecan
Drug
Lead sponsor
Martin Gutierrez
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 4, 2026, 7:51 PM EDT
Recruiting Phase 1 Interventional

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

NCT06582017
View directory record Official record
Conditions
Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma, Gastrointestinal Cancer, Lung Cancer, Prostate Cancer, Breast Cancer
Interventions
QXL138AM Injection every 2 weeks by IV Infusion
Biological
Lead sponsor
Nammi Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Newport, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 4, 2026, 7:51 PM EDT